Cargando…
Cytoreductive prostatectomy: Evidence in support of a new surgical paradigm (Review)
Prostate cancer (PCa) remains the second ranked cause of cancer deaths in the United States. The current standard of care for metastatic prostate cancer (mPCa) includes systemic therapies with no option for surgery. In contrast, in other malignancies such as breast and kidney cancer, cytoreduction p...
Autores principales: | FAIENA, IZAK, SINGER, ERIC A., PUMILL, CHRIS, KIM, ISAAC Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215584/ https://www.ncbi.nlm.nih.gov/pubmed/25340386 http://dx.doi.org/10.3892/ijo.2014.2656 |
Ejemplares similares
-
New Paradigms for Cytoreductive Nephrectomy
por: Lichtbroun, Benjamin J., et al.
Publicado: (2022) -
Multimodal treatments for advanced prostate cancer
por: Faiena, Izak, et al.
Publicado: (2019) -
Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy
por: Kim, Isaac Yi, et al.
Publicado: (2022) -
Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer
por: Yuh, Bertram E., et al.
Publicado: (2019) -
An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for Metastatic Prostate Cancer
por: Yanagisawa, Takafumi, et al.
Publicado: (2023)